# Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment

> **NCT01320111** · PHASE2 · COMPLETED · sponsor: **Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH** · enrollment: 59 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Paclitaxel and Sorafenib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01320111
- **Lead sponsor:** Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-01
- **Primary completion:** 2014-08-31
- **Final completion:** 2014-08-31
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2017-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01320111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01320111, "Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01320111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*